|
Mar 29 ,2023
Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting
|
|
Mar 23 ,2023
Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update
|
|
Mar 22 ,2023
Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders
|
|
Mar 21 ,2023
Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program
|
|
Mar 09 ,2023
Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
|
|
Feb 27 ,2023
Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium
|
|
Feb 02 ,2023
Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences
|
|
Jan 12 ,2023
Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference
|
|
Nov 10 ,2022
Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update
|
|
Sep 26 ,2022
Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson’s Disease Patient-Derived Dopaminergic Neurons
|
|
Sep 20 ,2022
Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer
|
|
Sep 08 ,2022
Gain Therapeutics to Present Data at Upcoming Medical Meetings
|
|
Sep 06 ,2022
Gain Therapeutics To Participate At The H.C. Wainwright 24th Annual Global Investment Conference
|
|
Aug 08 ,2022
Gain Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Business Update
|
|
Aug 04 ,2022
Gain Therapeutics to Participate at the 2022 BTIG Biotechnology Conference
|
|
Jun 02 ,2022
Gain Therapeutics to Participate at the Jefferies Healthcare Conference
|
|
May 18 ,2022
Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference
|
|
May 16 ,2022
Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update
|
|
May 11 ,2022
Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium
|
|
May 06 ,2022
Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at XXVII IAPRD World Congress
|
|
Apr 26 ,2022
Gain Therapeutics to Participate in the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
|
|
Apr 12 ,2022
Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at the 2022 Synuclein Meeting
|
|
Mar 29 ,2022
Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid and Sphingolipid Biology Gordon Research Conference
|
|
Mar 24 ,2022
Gain Therapeutics, Inc. Reports Full Year 2021 Financial Results and Business Update
|
|
Mar 15 ,2022
Gain Therapeutics Presents Positive Data on its Structurally Targeted Allosteric Regulators in both Parkinson’s and Alzheimer’s Disease at the AD/PD 2022 Conference
|
|
Mar 01 ,2022
Gain Therapeutics Announces Participation in Upcoming Investor and Scientific Conferences
|
|
Feb 08 ,2022
Gain Therapeutics Presents Preclinical Data on its Structurally Targeted Allosteric Regulators in GBA1 Gaucher Disease at the WORLDSymposium 2022
|
|
Feb 04 ,2022
Gain Therapeutics Outlines Key Objectives for 2022 Following its Inaugural R&D Day
|
|
Jan 31 ,2022
Gain Therapeutics Announces Additional Details on its February 4th Virtual R&D Day
|
|
Jan 18 ,2022
Gain Therapeutics Announces R&D Day Event and Participation in Upcoming Conferences
|
|
Jan 06 ,2022
Gain Therapeutics to Participate at the H.C. Wainwright Bioconnect Virtual Conference
|
|
Dec 28 ,2021
Gain Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Dec 07 ,2021
Gain Therapeutics Progresses Krabbe Disease Program and Provides Scientific Update
|
|
Dec 01 ,2021
Gain Therapeutics to Participate at the Imagine AI + Healthcare Investor Summit
|
|
Nov 12 ,2021
Gain Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Business Update
|
|
Nov 11 ,2021
Gain Therapeutics Presents Parkinson’s Disease Preclinical Study Results at Society for Neuroscience Annual Meeting
|
|
Nov 10 ,2021
Gain Therapeutics, Inc. Announces Breakthrough Pre-Clinical Data of Novel Small Molecules for the Treatment of Parkinson’s Disease and Gaucher Disease
|
|
Nov 04 ,2021
Gain Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference
|
|
Oct 28 ,2021
Gain Therapeutics to Present at Upcoming Medical Conferences
|
|
Oct 26 ,2021
Gain Therapeutics, Inc. Announces Appointment of Five Members to its Newly Formed Scientific Advisory Board (SAB)
|
|
Oct 19 ,2021
Gain Therapeutics Appoints Matthias Alder as Chief Operating Officer
|
|
Sep 23 ,2021
Gain Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
|
|
Sep 17 ,2021
Gain Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
|
|
Sep 09 ,2021
Gain Therapeutics to Present at 2021 International Virtual GM1 Community Conference
|
|
Sep 08 ,2021
Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson’s Disease
|
|
Sep 08 ,2021
Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson’s Disease
|
|
Sep 02 ,2021
Gain Therapeutics, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
|
|
Aug 11 ,2021
Gain Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Business Update
|
|
Aug 03 ,2021
Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference
|
|
Jun 10 ,2021
Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment of CNS Disorders
|
|
May 27 ,2021
Gain Therapeutics to Present at the Jefferies Virtual Healthcare Conference
|
|
May 17 ,2021
Gain Therapeutics to Participate in Upcoming Virtual Investor Conferences in May
|
|
May 10 ,2021
Gain Therapeutics, Inc. Reports First Quarter 2021 Financial Results
|
|
Apr 27 ,2021
Gain Therapeutics to Present at the B. Riley Securities’ Virtual Neuroscience Conference
|
|
Apr 22 ,2021
Gain Therapeutics Announces Presentation at the International Association of Parkinsonism and Related Disorders 2021 World Congress
|
|
Apr 20 ,2021
Gain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement with Zentalis Pharmaceuticals
|
|
Mar 25 ,2021
Gain Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Overallotment Option to Purchase Additional Shares
|
|
Mar 18 ,2021
Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock
|
|
Mar 10 ,2021
Gain Therapeutics Files Registration Statement with SEC for Proposed Initial Public Offering
|
|
Feb 04 ,2021
Gain Therapeutics Announces Three Late-Breaker Presentations at the 17th Annual WORLDSymposium
|
|
Feb 02 ,2021
Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors
|
|
Nov 30 ,2020
Gain Therapeutics and University of Maryland School of Medicine Announce Research Collaboration
|
|
Oct 13 ,2020
Gain Therapeutics to Present New Preclinical Data on Brain Penetrant Allosteric Regulators at the 14th Meeting of the European Working Group on Gaucher Disease
|
|
Sep 10 ,2020
Gain Therapeutics Announces Research Collaboration with Sumitomo Dainippon Pharma Co., Ltd to Advance Gain’s Lysosomal Enzyme Allosteric Regulator Program
|
|
Jul 21 ,2020
Gain Therapeutics, Inc. Announces Close of $10 Million Series B Financing
|
|
Sep 11 ,2019
Gain Therapeutics SA Announces Jeffrey Riley to join its Board of Directors
|